Adverse reactions in the treatment of patients with non-tuberculous lung mycobacterial pulmonary disease and the possibility of their solution

被引:0
作者
Vladimirova, Elena B. [1 ]
Shmelev, Evgene I. [1 ]
Zaytseva, Anna S. [1 ]
Kasimtseva, Svetlana A. [1 ]
Shchepikhin, Evgeniy I. [1 ]
Smirnova, Tatiana G. [1 ]
Makaryants, Natalia N. [1 ]
机构
[1] Cent Res Inst TB, Moscow, Russia
关键词
non-tuberculous mycobacterial pulmonary disease; adverse reactions; treatment; efficacy;
D O I
10.26442/00403660.2024.11.202992
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To study the adverse reactions that develop as a result of complex antibiotic therapy in patients with non-tuberculous lung mycobacterial (NTML) and to determine methods for their elimination without compromising the effectiveness of NTML treatment. Materials and methods. Examined 147 patients with confirmed NTML, for which they received treatment in accordance with the results of drug susceptibility of the pathogen. Before and during treatment, a study of clinical, biochemical blood tests, urinalysis, electrocardiogram, external respiration function, ultrasound of the abdominal organs and kidneys was performed. Results. Under the conditions of antimicrobial therapy (AMT) for non-tuberculous mycobacteriosis of the lungs, 41 (27.9%) patients developed adverse drug reaction (ADR). The most frequent adverse reactions were: allergic reactions in the form of urticaria, nausea, vomiting, arthralgia, nephroand ototoxic reactions; 34 (82.9%) patients required treatment adjustment without discontinuation of AMT, and only in 7 (17.1%) cases, AMT was discontinued. A full course of multicomponent AMT was completed in 124 (84.4%) patients with NTML. An algorithm for monitoring therapy in NTML patients from the standpoint of preventing ADR has been developed. The categories of patients with potential risks of developing ADR under AMT were determined. Patients without the development of ADR had a positive radiological dynamics in 27.9% of cases, sputum conversion - in 42%. Patients with ADR had positive clinical dynamics in 39% of cases, radiological - in 31.7% of cases, sputum conversion - in 36.6% of cases. Conclusion. The incidence of ADR development remains high when complex AMT is administered to patients with NTML. The patient's comorbid background is the main risk factor for the development of ADR when prescribing multicomponent AMT. A multivariate analysis of the effectiveness of treatment in NTML patients showed comparable data among patients taking complex AMT and receiving only alternative therapies. The success of NTML treatment depends on a comprehensive personalized approach.
引用
收藏
页码:1049 / 1055
页数:7
相关论文
共 11 条
[1]  
BmaAnnpoBa E., 2019, TepaeBuecku apuB, V91, P26
[2]   Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline [J].
Daley, Charles L. ;
Iaccarino, Jonathan M. ;
Lange, Christoph ;
Cambau, Emmanuelle ;
Wallace Jr, Richard J. ;
Andrejak, Claire ;
Boettger, Erik C. ;
Brozek, Jan ;
Griffith, David E. ;
Guglielmetti, Lorenzo ;
Huitt, Gwen A. ;
Knight, Shandra L. ;
Leitman, Philip ;
Marras, Theodore K. ;
Olivier, Kenneth N. ;
Santin, Miguel ;
Stout, Jason E. ;
Tortoli, Enrico ;
van Ingen, Jakko ;
Wagner, Dirk ;
Winthrop, Kevin L. .
EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (01)
[3]   Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline [J].
Daley, Charles L. ;
Iaccarino, Jonathan M. ;
Lange, Christoph ;
Cambau, Emmanuelle ;
Wallace, Richard J., Jr. ;
Andrejak, Claire ;
Boettger, Erik C. ;
Brozek, Jan ;
Griffith, David E. ;
Guglielmetti, Lorenzo ;
Huitt, Gwen A. ;
Knight, Shandra L. ;
Leitman, Philip ;
Marras, Theodore K. ;
Olivier, Kenneth N. ;
Santin, Miguel ;
Stout, Jason E. ;
Tortoli, Enrico ;
van Ingen, Jakko ;
Wagner, Dirk ;
Winthrop, Kevin L. .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) :905-913
[4]   Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy [J].
Jenkins, P. A. ;
Campbell, I. A. ;
Banks, J. ;
Gelder, C. M. ;
Prescott, R. J. ;
Smith, A. P. .
THORAX, 2008, 63 (07) :627-634
[5]   Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease [J].
Kamii, Y. ;
Nagai, H. ;
Kawashima, M. ;
Matsuki, M. ;
Nagoshi, S. ;
Sato, A. ;
Kohno, S. ;
Ohgiya, M. ;
Ohta, K. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (12) :1505-+
[6]   Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease [J].
Kim, Joong-Yub ;
Kim, Na Young ;
Jung, Hee-Won ;
Yim, Jae-Joon ;
Kwak, Nakwon .
BMC PULMONARY MEDICINE, 2022, 22 (01)
[7]   State-of-the-art treatment strategies for nontuberculous mycobacteria infections [J].
Munoz-Egea, Maria-Carmen ;
Carrasco-Anton, Nerea ;
Esteban, Jaime .
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (08) :969-981
[8]  
nna B.H., 2017, Kuuecka ukpo6uoou u auukpo6a uuoepau, V19, P276
[9]   Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system [J].
Ozawa, Takuya ;
Namkoong, Ho ;
Takaya, Risako ;
Takahashi, Yusuke ;
Fukunaga, Koichi ;
Enoki, Yuki ;
Taguchi, Kazuaki ;
Kizu, Junko ;
Matsumoto, Kazuaki ;
Hasegawa, Naoki .
BMC INFECTIOUS DISEASES, 2022, 22 (01)
[10]  
WHO, 1972, Tech Rep Ser WHO, P498